ADC Therapeutics CFO receives 203,700 RSUs
ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026. These RSUs vest on the earlier of June 30, 2027 or certain qualifying termination events, assuming continued employment. Each RSU converts into one common share, bringing his direct holdings to 938,076 common shares after the award.
Insider Trade Summary
Grant/Award: 203,700 shares
Grant/Award
1 txn
Insider
Carmona Jose
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Shares | 203,700 | $0.00 | $0.00 |
Holdings After Transaction:
Common Shares — 938,076 shares (Direct)
Footnotes (1)
- F1. Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Key Figures
RSUs granted: 203,700 units
Post-grant holdings: 938,076 shares
Grant price: $0.00 per unit
+1 more
4 metrics
RSUs granted
203,700 units
Restricted stock units granted on June 30, 2026
Post-grant holdings
938,076 shares
Common shares directly owned after RSU award
Grant price
$0.00 per unit
RSU award under incentive agreement
Vesting date
June 30, 2027
Time-based vesting unless earlier qualifying termination
Key Terms
restricted stock units ("RSUs"), incentive award letter agreement, vest, good reason, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents an award of restricted stock units ("RSUs") granted on June 30, 2026"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
incentive award letter agreement financial
"RSUs granted on June 30, 2026 pursuant to an incentive award letter agreement"
vest financial
"The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
good reason financial
"termination of employment by the Issuer without cause or by the reporting person for good reason"
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ADC Therapeutics (ADCT) disclose about CFO Jose Carmona in this Form 4?
ADC Therapeutics disclosed that CFO Jose Carmona received 203,700 restricted stock units on June 30, 2026. These equity awards increase his direct holdings to 938,076 common shares, reflecting stock-based compensation rather than an open-market purchase or sale.
How many restricted stock units did ADC Therapeutics grant to its CFO?
ADC Therapeutics granted its CFO, Jose Carmona, 203,700 restricted stock units as of June 30, 2026. Each RSU represents a contingent right to receive one common share, subject to vesting conditions tied to time and certain employment termination scenarios.
When do Jose Carmona’s ADC Therapeutics RSUs vest?
The RSUs granted to Jose Carmona vest on the earlier of June 30, 2027 or his termination by ADC Therapeutics without cause, or his resignation for good reason. Vesting is conditioned on his continued employment with the company through the applicable vesting date.
Is the ADC Therapeutics CFO Form 4 transaction a market buy or sell?
The Form 4 shows a grant or award acquisition, not a market trade. Jose Carmona received 203,700 restricted stock units at a price of $0.00 per unit as part of compensation, rather than buying or selling shares in the open market.
What conditions affect the vesting of ADC Therapeutics CFO RSUs?
The RSUs vest upon the earlier of June 30, 2027, or if ADC Therapeutics terminates the CFO without cause, or he resigns for good reason. Vesting remains subject to his continued employment with the issuer through the relevant vesting date under the incentive agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
